### Highlights of This Issue 2823

#### REVIEW

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2825</td>
<td>Mechanisms of Resistance to Antibody–Drug Conjugates</td>
<td>Frank Loganzo, Matthew Sung, and Hans-Peter Gerber</td>
</tr>
</tbody>
</table>

#### SMALL MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2835</td>
<td>Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth</td>
<td>Jun Chen, Taisei Kinoshita, Juthamas Sukbuntherng, Betty Y. Chang, and Laurence Elias</td>
</tr>
<tr>
<td>2845</td>
<td>Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations</td>
<td>Yemarshet K. Gebreyohannes, Patrick Schoffski, Thomas Van Looy, Jasmien Wellens, Lise Vreys, Jasmien Cornillie, Ulla Vanleeuw, Dana T. Aftab, Maria Debiec-Rychier, Raf Sciort, and Agnieszka Wozniak</td>
</tr>
<tr>
<td>2863</td>
<td>Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells</td>
<td>Eiman Mukhtar, Vaqar Mustafa Adhami, Imtiar Ahmad Siddiqui, Ajit Kumar Verma, and Hasan Mukhtar</td>
</tr>
<tr>
<td>2875</td>
<td>Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer</td>
<td>Stepana Boukalova, Jan Stursa, Lukas Werner, Zuzana Ezrova, Jiri Cerny, Ayenachew Beazwork-Geleta, Alena Pecinova, Lanfeng Dong, Zdenek Drahota, and Jiri Neuzil</td>
</tr>
<tr>
<td>2887</td>
<td>Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer</td>
<td>Jianfeng Lu, Donna Mclauchern, Shunjiang Li, Matthew J. Ellis, and Shaomeng Wang</td>
</tr>
</tbody>
</table>

#### LARGE MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2894</td>
<td>Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer</td>
<td>Yan Huang, Lenard M. Lichtenberger, Morgan Taylor, Justin N. Botsford-Miller, Monika Haemmerle, Michael J. Wagner, Yasmin Lyons, Sunila Pradeep, Wei Hu, Rebecca A. Previs, Jean M. Hansen, Desing Fang, Piotr L. Domniak, Justyna Filant, Elizabeth J. Dial, Fangrong Shen, Hiroto Hatakeyama, and Anil K. Sood</td>
</tr>
<tr>
<td>2905</td>
<td>Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells</td>
<td>Sagar Uttarkar, Therese Piontek, Sandeep Dukare, Caroline Schomburg, Peter Schlenke, Wolfgang E. Berdel, Carsten Muller-Tidow, Thomas J. Schmidt, and Karl-Heinz Klimpauer</td>
</tr>
<tr>
<td>2916</td>
<td>CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation</td>
<td>Dan-Dan Wang, Ying Chen, Zi-Bo Chen, Fang-Jie Yan, Xiao-Yang Yang, Mei-Dan Ying, Ji Cao, Jian Ma, Pei-Hua Luo, Yong-Xin Han, Yong Peng, Ying-Hui Sun, Hui Zhang, Qiao-Jun He, Bo Yang, and Hong Zhu</td>
</tr>
<tr>
<td>2926</td>
<td>Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma</td>
<td>Samuele Cazzamalli, Alberto Dal Corso, and Dario Neri</td>
</tr>
</tbody>
</table>

#### LARGE MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
### Table of Contents

#### CANCER BIOLOGY AND SIGNAL TRANSDUCTION

2955  **Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome**  
Miao Liu, Li-Xing Feng, Peng Sun, Wang Liu, Tian Mi, Min Lei, Wanying Wu, Baosheng Jiang, Min Yang, Lihong Hu, De-An Guo, and Xuan Liu

2956  **Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma**  
Xiaoyun Dai, Kwang Seok Ahn, Ling Zhi Wang, Chulwon Kim, Amudha Deivasigamni, Frank Arfuso, Jae-Young Um, Alan Prem Kumar, Young-Chae Chang, Dhiraj Kumar, Gopal C. Kundu, Junji Magae, Boon Cher Goh, Kam Man Hui, and Gautam Sethi

2977  **The Potential Roles of Long Noncoding RNAs (IncRNA) in Glioblastoma Development**  
Shuang Liu, Ramkrishna Mitra, Ming-Ming Zhao, Wenfong Fan, Christine M. Eischen, Feng Yin, and Zhongming Zhao

2987  **The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells**  
Teresa Delgado-Goni, Maria Falck Miniotis, Slawomir Wantuch, Harold G. Parkes, Richard Marais, Paul Workman, Martin O. Leach, and Mounia Beloueche-Babari

3000  **Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis**  
Alfeu Zanotto-Filho, V. Pragathi Masamsetti, Aparna Gorthi, Xavier Bernard, Rosangela Mayer Goncalves, Jos C.F. Moreira, Yidong Chen, and Alexander J.R. Bishop

3015  **Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer**  
Hisato Kawakami, Shengbing Huang, Krishnendu Pal, Shamit K. Dutta, Debaratra Mukhopadhyay, and Frank A. Sinclair

3028  **Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors**  
Timothy A. Marlowe, Felicia L. Lenzo, Sheila A. Figel, Abigail T. Grapes, and William G. Cance

3040  **Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation**  
Toshimitsu Yamaoka, Tohru Ohnori, Motoi Ohba, Satoru Arata, Yasunari Kishino, Yasunori Murata, Sojiro Kusumoto, Hiroo Ishida, Takao Shirai, Takashi Hirose, Tsukasa Ohnishi, and Yasutsuna Sasaki

3055  **STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A**  
Shuo Wang, Cedric Darini, Laurent Desaube, and Antonis E. Koromilas

3064  **Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model**  
Gina Lee, Brenda Auffinger, Donna Guo, Tanvir Hasan, Marc Deheeger, Alex L. Tobias, Jeong Yeon Kim, Fatemeh Atashi, Lingjiiao Zhang, Maciej S. Lesniak, C. David James, and Atique U. Ahmed

#### COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

3077  **Macrophage Susceptibility to Emactuzumab (RG7155) Treatment**  
Leon P. Pradel, Chia-Huey Ooi, Solange Romagnoli, Michael A. Cannarile, Dominik Ruttinger, and Carola H. Ries

3087  **ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis**  
Vinod Vijay Subhash, Shi Hui Tan, Mei Shi Yeo, Fui Leng Yan, Praveen C. Peethala, Natalia Lien, Shi Hui Tan, and Wei Peng Yong

#### MODELS AND TECHNOLOGIES

3097  **Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors**  
Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Nicole Willemsen-Seegers, Judith R.F. de Vetter, Jelle Dylus, Antoon M. van Doornmalen, Jeffrey Kooijman, Massaki Saw, Suzanne J.C. van Gerwen, Jos de Man, Rogier C. Buisman, and Guido J.R. Zaman
3110 Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Miro J. Eigenmann, Nicolas Frances, Gerhard Hoffmann, Thierry Lavé, and Antje-Christine Walz

3120 Correction: Antagonists of IGF: Vitronectin Interactions Inhibit IGF-I–Induced Breast Cancer Cell Functions

3121 Acknowledgment to Reviewers

ABOUT THE COVER
The cover image shows a Pearson correlation matrix of 51 anti-cancer agents analyzed in the Oncolines and NCI-60 cancer cell line panels (blue: high correlation, orange: negative correlation). The left triangle shows clusters and correlations using data from the Oncolines panel. The right triangle is identical to the left one, only based on NCI-60 data. Both data sets reveal similar clusters (some classes are indicated). Read more on the Oncolines™ cancer cell line profiling study in the article by Uitdehaag and colleagues from page 3097 of this issue.
Molecular Cancer Therapeutics

15 (12)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/15/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/15/12. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.